Centauri Therapeutics raises £24 million to advance anti-microbial resistance research
Centauri Therapeutics, an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, has closed a £24 million (US$32 million) Series A investment round. The funds will support the continued advancement of the company’s antimicrobial resistance (AMR) research and development, using the Alphamer platform to identify and progress novel antibacterial […]
